SARS-CoV-2 Archives - Page 4 of 8 - Dr Amin Azhari

Emergency department visits related to opioid overdoses up significantly during COVID-19 pandemic

Emergency department visit rates because of an opioid overdose increased by 28.5% across the U.S. in 2020, compared to 2018 and 2019, recent Mayo Clinic research finds. Emergency visits overall decreased by 14% last year, while visits because of an opioid overdose increased by 10.5%. The result: Opioid overdoses were responsible for 0.32 out of 100 visits, or 1 in every 313 visits, which is up from 0.25, or 1 in every 400 visits, the previous two years.

This trend is supported by preliminary data recently released by the Centers for Disease Control and Prevention (CDC), which recorded more than 93,000 opioid overdose deaths in 2020. That’s a 29.4% increase from the year prior and the most opioid overdose deaths every recorded in the U.S.

The research was published in the Annals of Emergency Medicine and was presented in June at the AcademyHealth annual research meeting. The research also was presented at the Society for Academic Emergency Medicine’s conference, where it was selected for a plenary session.

Release date: 26 July 2021
Source: Mayo Clinic

Common COVID-19 Antibiotic No More Effective Than Placebo

A UC San Francisco study has found that the antibiotic azithromycin was no more effective than a placebo in preventing symptoms of COVID-19 among non-hospitalized patients, and may increase their chance of hospitalization, despite widespread prescription of the antibiotic for the disease.

Azithromycin, a broad-spectrum antibiotic, is widely prescribed as a treatment for COVID-19 in the United States and the rest of the world. “The hypothesis is that it has anti-inflammatory properties that may help prevent progression if treated early in the disease,” said Oldenburg. “We did not find this to be the case.”

The study included 263 participants who all tested positive for SARS-CoV-2 within seven days before entering the study. None were hospitalized at the time of enrollment. In a random selection process, 171 participants received a single, 1.2 gram oral dose of azithromycin and 92 received an identical placebo.

At day 14 of the study, 50 percent of the participants remained symptom-free in both groups. By day 21, five of the participants who received azithromycin had been hospitalized with severe symptoms of COVID-19 and none of the placebo group had been hospitalized.

The researchers concluded that treatment with a single dose of azithromycin compared to placebo did not result in greater likelihood of being symptom-free.

The study, which was conducted in collaboration with Stanford University, appears in the JAMA.

Release date: 16 July 2021
Source: University of California – San Francisco

COVID-19 antibodies persist at least nine months after infection

Testing of an entire Italian town shows antibody levels remain high nine months after SARS-CoV-2 infection, whether symptomatic or asymptomatic.

Researchers from the University of Padua and Imperial College London tested more than 85 percent of the 3,000 residents of Vo’, Italy, in February/March 2020 for infection with SARS-CoV-2, the virus that causes COVID-19, and tested them again in May and November 2020 for antibodies against the virus.

The team found that 98.8 percent of people infected in February/March showed detectable levels of antibodies in November, and there was no difference between people who had suffered symptoms of COVID-19 and those that had been symptom-free. The results are published in Nature Communications.

Release date: 19 July 2021
Source: Imperial College London

Common Medication Used to Reduce Cholesterol Levels May Reduce COVID-19 Severity

Using anonymized medical records from a national registry, UC San Diego researchers confirm earlier findings that statins may substantially minimize adverse outcomes from SARS-CoV-2 infection.

In a new study from University of California San Diego School of Medicine, researchers have confirmed that patients taking statin medications had a 41 percent lower risk of in-hospital death from COVID-19. The findings were published in PLOS ONE and expand upon prior research conducted at UC San Diego Health in 2020.

Statins are commonly used to reduce blood cholesterol levels by blocking liver enzymes responsible for making cholesterol. They are widely prescribed: The Centers for Disease Control estimates that 93 percent of patients who use a cholesterol-lowering drug use a statin.

Release date: 25 July 2021
Source: University of California – San Diego

“Long COVID”: More than a quarter of COVID-19 patients still symptomatic after 6 months

In a new study of adults from the general population who were infected with COVID-19 in 2020, more than a quarter report not having fully recovered after six to eight months. Those findings are described in the open-access journal PLOS ONE.

In the new study, researchers recruited 431 participants from within the contact tracing system in Zurich, Switzerland. All participants had tested positive for SARS-CoV-2 between February and August 2020, and completed an online questionnaire about their health a median of 7.2 months after their diagnosis. Symptoms had been present at diagnosis in 89% of the participants and 19% were initially hospitalized. Compared to individuals not participating in the study, participants were younger–with an average age of 47.

Overall, 26% of participants reported that they had not fully recovered at six to eight months after initial COVID-19 diagnosis. 55% reported symptoms of fatigue, 25% had some degree of shortness of breath, and 26% had symptoms of depression. A higher percentage of females and initially hospitalized patients reported not having recovered compared to males and non-hospitalized individuals. A total of 40% of participants reported at least one general practitioner visit related to COVID-19 after their acute illness. The authors say that their findings underscore the need for the timely planning of resources and patient services for post-COVID-19 care.

Release date: 13 July 2021
Source: EurekAlert

Public Health

Moderna and Pfizer-BioNTech vaccines prime T cells to fight SARS-CoV-2 variants

Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants.

Their new study, published in Cell Reports Medicine, shows that both CD4+ “helper” T cells and CD8+ “killer” T cells can still recognize mutated forms of the virus. This reactivity is key to the body’s complex immune response to the virus, which allows the body to kill infected cells and stop severe infections.

Release date: 01 July 2021
Source: La Jolla Institute for Immunology

How a corona infection changes blood cells in the long run

Using real-time deformability cytometry, researchers at the Max-Planck-Zentrum für Physik und Medizin in Erlangen were able to show for the first time: Covid-19 significantly changes the size and stiffness of red and white blood cells – sometimes over months. These results may help to explain why some affected people continue to complain of symptoms long after an infection (long covid).

Shortness of breath, fatigue and headaches: some patients still struggle with the long-term effects of a severe infection by the SARS-CoV-2 coronavirus after six months or more. This post Covid-19 syndrome, also called long covid, is still not properly understood. What is clear is that — during the course of the disease — often blood circulation is impaired, dangerous vascular occlusions can occur and oxygen transport in is limited. These are all phenomena in which the blood cells and their physical properties play a key role.

The research group has now published their results in the renowned journal “Biophysical Journal“.

Release date: 17 Jun 2021
Source: Max-Planck-Gesellschaft

COVID-19 Linked to Alzheimer’s Disease-like Cognitive Impairment

A new Cleveland Clinic-led study has identified mechanisms by which COVID-19 can lead to Alzheimer’s disease-like dementia. The findings, published in Alzheimer’s Research & Therapy, indicate an overlap between COVID-19 and brain changes common in Alzheimer’s, and may help inform risk management and therapeutic strategies for COVID-19-associated cognitive impairment.

Reports of neurological complications in COVID-19 patients and “long-hauler” patients whose symptoms persist after the infection clears are becoming more common, suggesting that SARS-CoV-2 (the virus that causes COVID-19) may have lasting effects on brain function. However, it is not yet well understood how the virus leads to neurological issues.

Release date: 10 Jun 2021
Source: Cleveland Clinic

Dental procedures during pandemic are no riskier than a drink of water

A new study’s findings dispel the misconception that patients and providers are at high risk of catching COVID-19 at the dentist’s office.

SARS-CoV-2 spreads mainly through respiratory droplets, and dental procedures are known to produce an abundance of aerosols – leading to fears that flying saliva during a cleaning or a restorative procedure could make the dentist’s chair a high-transmission location.

Ohio State University researchers set out to determine whether saliva is the main source of the spray, collecting samples from personnel, equipment and other surfaces reached by aerosols during a range of dental procedures.

By analyzing the genetic makeup of the organisms detected in those samples, the researchers determined that watery solution from irrigation tools, not saliva, was the main source of any bacteria or viruses present in the spatter and spurts from patients’ mouths.

Even when low levels of the SARS-CoV-2 virus were detected in the saliva of asymptomatic patients, the aerosols generated during their procedures showed no signs of the coronavirus. In essence, from a microbial standpoint, the contents of the spray mirrored what was in the office environment.

The study was published in the Journal of Dental Research.

Release date: 13 May 2021
Source: Ohio State University

Public Health, Public Health, Public Health, Public Health, Public Health, Public Health, Public Health, Public Health, Public Health

One third of patients hospitalised with severe COVID-19 still have lung changes after a year

A new study has shown that most patients discharged from hospital after experiencing severe COVID-19 infection appear to return to full health, although up to a third do still have evidence of effects upon the lungs one year on.

COVID-19 has infected millions of people worldwide. People are most commonly hospitalised for COVID-19 infection when it affects the lungs – termed COVID-19 pneumonia. Whilst significant progress has been made in understanding and treating acute COVID-19 pneumonia, very little is understood about how long it takes for patients to fully recover and whether changes within the lungs persist.

In this new study, published in The Lancet Respiratory Medicine, researchers from the University of Southampton worked with collaborators in Wuhan, China, to investigate the natural history of recovery from severe COVID-19 pneumonia up to one year after hospitalisation.

Release date: 06 May 2021
Source: University of Southampton

Tag Archive for: SARS-CoV-2